文献速递腹部技术与安全US

以组织病理学为金标准,采用超声造影对结直肠癌肝转移患者新辅助治疗反应进行分类

Classification of Neoadjuvant Therapy Response in Patients With Colorectal Liver Metastases Using Contrast-Enhanced Ultrasound-With Histological Pathology as the Gold Standard.
PubMed 文献 · Ultrasound Med Biol · 2024-10-15

本研究纳入2022年2月至12月收治的可切除结直肠癌肝转移患者,在新辅助治疗至少4个周期后、肝切除术前两周内行超声及超声造影检查,以病理肿瘤消退分级为金标准,构建基于超声的列线图模型区分反应组(TRG1/2/3)与无反应组(TRG4/5)。共分析105个病灶,43.8%对治疗有反应;多因素分析显示超声造影增强模式、廓清类型及坏死为独立相关因素,列线图AUC为0.898。

要点

  • 超声造影增强模式、廓清类型及坏死是结直肠癌肝转移新辅助治疗反应的独立预测因素。
  • 基于上述三个独立预测因素构建的列线图模型AUC为0.898。
  • 超声及超声造影参数(钙化、增强程度、供血动脉、微血流模式)与病理肿瘤消退分级显著相关。

核心结论

  • 基于超声的模型能准确评估结直肠癌肝转移患者术前化疗后的病理肿瘤反应,可能有助于决定个体化治疗策略。

研究设计与样本

  • 研究纳入2022年2月至12月收治的可切除结直肠癌肝转移患者,新辅助治疗至少4个周期后、肝切除术前两周内行超声及超声造影检查,造影 clips 经彩色参数成像(CPI)及微血流成像(MFI)后处理分析,以病理肿瘤消退分级为金标准,采用逻辑回归构建列线图,在病灶水平区分反应组(TRG1/2/3)与无反应组(TRG4/5),共分析105个病灶(每位患者分析直径最大的病灶)。

关键影像表现/征象

  • 单因素分析显示超声钙化(p=0.039)、超声造影增强程度(p<0.001)、超声造影增强模式(p<0.001)、超声造影廓清类型(p<0.001)、超声造影坏死(p<0.001)、CPI供血动脉(p=0.003)及MFI模式(p<0.001)与肿瘤消退分级显著相关。
  • 多因素分析显示超声造影增强模式(p=0.026)、超声造影廓清类型(p=0.018)及超声造影坏死(p=0.005)与新辅助治疗反应独立相关。
  • 105个病灶中43.8%对治疗有反应。

诊断标准与关键数值

  • 以病理肿瘤消退分级为金标准,反应组为TRG1/2/3,无反应组为TRG4/5。
  • 基于超声造影增强模式、超声造影廓清类型及超声造影坏死三个独立预测因素构建的列线图AUC为0.898。
  • 模型预测能力采用C指数及校准曲线评估,决策曲线分析评估列线图的附加价值。

临床应用与阅片要点

  • 在新辅助治疗至少4个周期后、肝切除术前两周内行超声及超声造影检查,可结合CPI及MFI后处理分析评估肿瘤消退分级。
  • 阅片时关注超声钙化、超声造影增强程度、增强模式、廓清类型、坏死、CPI供血动脉及MFI模式等与肿瘤消退分级相关的征象。
  • 基于超声造影增强模式、廓清类型及坏死构建的列线图AUC为0.898,可能有助于决定个体化治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the response to neoadjuvant therapy in patients with colorectal liver metastases (CRLMs) using ultrasound(US) and contrast-enhanced ultrasound(CEUS), with correction to the tumor regression grade (TRG) of pathological results.

METHODS: This study included patients with resectable CRLMs admitted from February to December 2022. After at least 4 cycles neoadjuvant therapy, all the patients received US and CEUS examinations within two weeks before hepatectomy. CEUS clips were postprocessed with color parameter imaging (CPI) and microflow imaging (MFI) analysis. Logistic regression analyses were used to develop an evaluation Nomogram. Ultrasound-based model was constructed to discriminate between the response (TRG1/2/3) and nonresponse (TRG4/5) groups at the lesion level. The model's predictive ability was evaluated using the C index and calibration curve, with decision curve analysis assessing the Nomogram's added value.

RESULTS: The study analyzed 105 CRLM lesions (the lesion with the highest diameter analyzed for each patient), with 43.8% showing a response to therapy. Univariate analysis identified calcification on US (p = 0.039), CEUS enhancement degree (p < 0.001), CEUS enhancement pattern (p<0.001), CEUS washout type (p < 0.001), CEUS necrosis (p < 0.001), CPI feeding artery (p = 0.003) and MFI pattern (p < 0.001) were significantly associated with TRG. The multivariate analysis showed CEUS enhancement pattern (p = 0.026), CEUS washout type (p = 0.018) and CEUS necrosis (p = 0.005) were independently associated with the neoadjuvant therapy response. A Nomogram with the three independent predictors was developed, with an AUC of 0.898.

CONCLUSION: The ultrasound-based model provided accurate evaluation of pathological tumor response to preoperative chemotherapy in patients with CRLM, and may help to decide the individualized treatment strategy.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Liu L, Cui WC, Sun Y, et al. Classification of Neoadjuvant Therapy Response in Patients With Colorectal Liver Metastases Using Contrast-Enhanced Ultrasound-With Histological Pathology as the Gold Standard. Ultrasound Med Biol. 2024. PMID: 39414406. doi:10.1016/j.ultrasmedbio.2024.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。